Article Figures & Data
- Figure 1.
Overlapping ascertainment of the groups used in the study. 1. Labeled as gout. 2. Allopurinol prescription. 3. Colchicine prescription.
- Figure 2.
The crude prevalence of gout by age and sex.
Factor Gout Population Crude Prevalence, % Relative Risk (95% CI) p Sex* Female 4185 783,049 0.53 1.00 Male 18,583 696,400 2.67 4.78 (4.53–5.05) < 0.0001 Smoking status Nonsmoker 3734 164,032 2.28 1.00 Ex-smoker 3066 58,618 5.23 1.18 (1.13–1.24) < 0.0001 Smoker 1605 99,628 1.61 0.76 (0.72–0.81) < 0.0001 Age group, years 20–24 66 131,606 0.05 1.00 25–29 191 181,792 0.11 2.25 (1.38–3.65) 0.001 30–34 435 179,524 0.24 5.32 (3.38–8.37) < 0.0001 35–39 646 149,358 0.43 9.2 (5.9–14.35) < 0.0001 40–44 1109 142,190 0.78 16.32 (10.54–25.27) < 0.0001 45–49 1383 121,326 1.14 23.34 (15.1–36.06) < 0.0001 50–54 1701 116,694 1.46 29.57 (19.16–45.64) < 0.0001 55–59 2034 105,049 1.94 39.92 (25.89–61.55) < 0.0001 60–64 2637 95,807 2.75 55.66 (36.13–85.74) < 0.0001 65–69 2849 85,236 3.34 64.27 (41.72–99.01) < 0.0001 70–74 2625 60,150 4.36 80.43 (52.2–123.95) < 0.0001 75–79 2452 44,142 5.55 97.3 (63.12–150) < 0.0001 80–84 2121 31,559 6.72 113.06 (73.31–174.37) < 0.0001 85+ 2519 35,016 7.19 121.73 (78.96–187.68) < 0.0001 Socioeconomic status 1 4339 286,008 1.52 1.00 2 4759 306,460 1.55 1.15 (1.06–1.24) 0.001 3 4224 281,400 1.5 1.24 (1.15–1.34) < 0.0001 4 5240 284,295 1.84 1.71 (1.59–1.84) < 0.0001 5 4119 305,623 1.35 1.04 (0.97–1.12) 0.306 ↵* Data not available for all patients.
No. SU tested Reference Population Proportion All gout 12,446 22,776 54.6% Gout, taking allopurinol 7979 12,975 61.5% Gout, not taking allopurinol 4467 9801 45.6%
Supplementary Materials
Supplementary data for this article are available online at jrheum.org.
Additional Files
Data Supplement
Data Supplement
Files in this Data Supplement:
- Data Supplement - Data Supplement
In this issue
An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population
